Perrigo Invests in Technology to Block Illegal Methamphetamine Production
By

By
Perrigo has signed an exclusive licensing agreement with Highland Pharmaceuticals, a St. Louis, Missouri-based pharmaceutical company, for Highland’s Tarex methamphetamine-blocking technology and the distribution rights of Zephrex-D (pseudoephedrine HCI 30…

Bayer, DelSiTech Partner for Drug Delivery Technology
By

By
Bayer has formed a collaboration and technology license agreement with DelSiTech, a Turku, Finland-based drug delivery and development company that focuses on biodegradable silica-based drug delivery technology, for the application…

Teva, Nanolek Partner for Production in Russia
By

By
Teva Pharmaceutical has signed an agreement with Nanolek, a Moscow, Russia-based biopharmaceutical company, to transfer production of a number of sterile injectable products to Nanolek’s site in Russia. The transfer…

BI, ViraTherapeutics in Immuno-Oncology Pact
By

By
Boehringer Ingelheim (BI) has formed a long-term collaboration with ViraTherapeutics, an Innsbruck, Austria-based biopharmaceutical company focused on anti-cancer therapeutics, to jointly develop an oncolytic virus therapy platform and to investigate…

Genentech, Hanmi Form Cancer-Drug Pact Worth Over $910 Million
By

By
Genentech, a Roche Group company, has signed an exclusive development and license agreement with Hanmi Pharmaceutical, a Seoul, South Korea-based pharmaceutical company, to develop and commercialize Hanmi’s pan-RAF inhibitor, HM95573,…

Medigene, Bluebird Bio in Cancer Pact Worth Over $1.15 billion
By

By
Medigene, a Martinsried, Germany-based biotechnology company focused on personalized T-cell-based immunotherapies, has entered a research and development (R&D) collaboration and licensing agreement with bluebird bio, a Cambridge, Massachusetts-based clinical-stage gene…

AstraZeneca, Allergan Partner for Crohn’s Disease Drug in Deal Worth Up to $1.52 Billion
By

By
AstraZeneca, through MedImmune, its biologics research and development arm, has entered into a licensing agreement with Allergan for the global rights to MedImmune’s anti-inflammatory candidate, MEDI2070, an interleukin-23 monoclonal antibody…

GlaxoSmithKline Completes Sale of Aspen
By

By
GlaxoSmithKline (GSK) has completed the sale of its remaining 28.2 million ordinary shares in Aspen Pharmacore Holdings at a price of South African Rand (ZAR) 300 ($21.74) per share, raising…

BD Invests $100 Million to Expand Insulin Syringe Manufacturing
By

By
Becton, Dickinson and Company (BD), a Franklin Lakes, New Jersey-based medical technology company, has announced it is investing $100 million to expand capacity for its insulin syringe manufacturing operations at…

Novo Nordisk to Cut Workforce by 1,000
By

By
Novo Nordisk intends to reduce its 42,300-person workforce by approximately 1,000 employees as part of its plan to reduce operating costs. The company said in a statement that it is…